BiologicalDrug
IMA950 clinical trials
Also written IMA 950.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
4 studies that test it; most in 2010 (1)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 3
University Hospital, Geneva (2) · Cancer Research UK (1) · Immatics Biotechnologies GmbH (1)
Often tested with
Tested in the same studies.
Poly ICLC (2) · Pembrolizumab (1) · Temozolomide (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1)
Studies
Open first, then newest update. How each study uses IMA950 is read from its arms, and is right about nine times in ten.
Testing it · 4
- Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing GlioblastomaCompletedPhase 1/2University Hospital, GenevaNCT03665545Written as IMA950/Poly-ICLC
- Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in GlioblastomaCompletedPhase 1/2University Hospital, GenevaNCT01920191Written as IMA 950
- Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma MultiformeCompletedPhase 1Cancer Research UKNCT01222221Written as glioblastoma multiforme multipeptide vaccine IMA950
- Peptide-based Glioma Vaccine IMA950 in Patients With GlioblastomaTerminatedPhase 1Immatics Biotechnologies GmbHNCT01403285Written as IMA950 plus GM-CSF